Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Current Taxes (2020 - 2023)

Cytek Biosciences filings provide 4 years of Current Taxes readings, the most recent being $246000.0 for Q2 2023.

  • On a quarterly basis, Current Taxes changed N/A to $246000.0 in Q2 2023 year-over-year; TTM through Jun 2023 was $246000.0, a N/A change, with the full-year FY2022 number at $1.4 million, down 42.61% from a year prior.
  • Current Taxes hit $246000.0 in Q2 2023 for Cytek Biosciences, roughly flat from $246000.0 in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $2.7 million in Q1 2022 to a low of $158000.0 in Q2 2021.
  • Median Current Taxes over the past 4 years was $480500.0 (2020), compared with a mean of $1.0 million.
  • Biggest five-year swings in Current Taxes: soared 429.06% in 2021 and later crashed 91.03% in 2023.
  • Cytek Biosciences' Current Taxes stood at $468000.0 in 2020, then soared by 429.06% to $2.5 million in 2021, then tumbled by 42.61% to $1.4 million in 2022, then crashed by 82.69% to $246000.0 in 2023.
  • The last three reported values for Current Taxes were $246000.0 (Q2 2023), $246000.0 (Q1 2023), and $1.4 million (Q4 2022) per Business Quant data.